DDInter604 DDInter1082
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Drospirenone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Drospirenone {u} (Compound) binds {v} (Gene) PTGS2
Drospirenone {u} (Compound) palliates {v} (Disease) polycystic ovary syndrome
Drospirenone {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Drospirenone {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Drospirenone (Compound) resembles Flurandrenolide (Compound)
Drospirenone (Compound) resembles Progesterone (Compound)
Drospirenone (Compound) binds PTGS2 (Gene)
Drospirenone (Compound) palliates polycystic ovary syndrome (Disease)
Drospirenone (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Drospirenone (Compound) causes Uterine haemorrhage (Side Effect)